Office of Sponsored Programs
OSP Weekly
03/07/2019
|
|
Please forward and share with other faculty who may be interested.
|
|
|
|
Looking for Funding?
Here are several sources, right at your fingertips to begin your search for sponsored program funding:
|
|
NIH Early Stage Investigator: Updating Eligibility Status After Submission
T
o minimize the need for manual change requests after submission, the updated policy (
NOT-OD-19-072
)
now allows NIH to automatically update the ESI status of an application with eRA Commons to reflect the following:
1. Applications will be reviewed with the designation assigned at the time of submission when applicants update educational credentials, residency, etc. information after submission of an R01 or R01-equivalent application, or if an investigator requests and/or receives an extension of ESI status after submitting an R01 or R01-equivalent application; and
2. If an ESI-eligible application is awarded, and has an R01 or R01-equivalent application pending review, the pending application will be reviewed as an ESI-eligible application.
|
|
NSF CAREER Webinar Announced
The National Science Foundation (NSF) announces a webinar to discuss the Faculty Early Career Development (
CAREER
) Program. CAREER is designed to support early-career faculty in the integration of research and education. The program is cross-listed for all NSF directorates, allowing proposals from a wide variety of scientific disciplines.
The webinar will serve as an opportunity to discuss proposal development and eligibility requirements with relevant NSF staff. It will be held on May 9, 2019 from 2:00 p.m. to 4:00 p.m. ET.
Register online
to attend.
Deadlines for CAREER proposals vary by NSF directorate.
|
|
NSF Funding Opportunity: Harnessing the Data Revolution
The National Science Foundation’s (NSF) Harnessing the Data Revolution (HDR) Big Idea is a national-scale activity to enable new modes of data-driven discovery that will allow new fundamental questions to be asked and answered at the frontiers of science and engineering. Through this NSF-wide activity, HDR will generate new knowledge and understanding, and accelerate discovery and innovation. Funding opportunities are currently available through this program.
Learn More
|
|
DOE to Provide $12 Million for Research on Quantum Physics
U.S. Department of Energy (DOE) announced a plan to provide $12 million for new research on Quantum Information Science (QIS) for particle physics. QIS seeks to harness exotic quantum properties of matter for computing, information processing, and other applications. The current initiative will explore potential synergies and connections between QIS and particle physics, with the aim of promoting progress in both fields. Funding opportunities are currently available.
Learn More
|
|
NIH Releases FOAs for HIV/AIDS Clinical Trials
Every seven years, NIH competitively renews funding for the HIV/AIDS clinical trials networks. Recently reissued Funding Opportunity Announcements (FOAs) will renew funding of the networks through 2027. The six January 24, 2019 FOAs involve large-scale, multi-site clinical research activities. Applications are open and funding is currently available.
Learn More
|
|
School of Medicine Opportunity
|
|
Global Medical Grants
Pfizer Global Medical Grants (GMG), Merck KGaA, Darmstadt, Germany - Global Medical Education (GME), and EMD Serono, Inc. US Medical Education are collaborating to provide grant support for continuing professional education in the area of Immuno-Oncology. Immuno-Oncology is a top priority for Merck KGaA, Darmstadt, Germany, EMD Serono, Inc. and Pfizer Inc, and for the Global Strategic Alliance among our organizations.
|
|
Request for Proposals (RFP)
2019 Advances in Immuno-Oncology in Renal Cell Carcinoma
|
|
Date RFP Issued
: March 7, 2019
Geographic Scope
:
North America: Canada, United States
Europe: France, Germany, Italy, Spain, Switzerland, United Kingdom
Asia Pacific: Australia, Japan, Taiwan
Latin America: Argentina, Brazil
Clinical Area
:
Immuno-Oncology in Renal Cell Carcinoma
Application Due Date
: April 11, 2019
Specific Area of Interest
:
It is our intent to support projects specifically in renal cell carcinoma that:
- Increase understanding of the rationale for consideration of IO combination therapies in the treatment of RCC including IO/VEGFR TKI and IO/IO.
- Increase awareness of when immunotherapy should be considered as a treatment option for patients with RCC to include patient selection, optimal drug combinations, and sequencing.
- Improve the early detection and management of IO and IO combination (IO/VEGFR TKI or IO/IO) related adverse events in RCC patients.
|
|
|
|
|
|
|
